StockData
Crescent Biopharma, Inc. logo

Crescent Biopharma, Inc. (CBIO) stock

CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$12.40−0.64 (-4.91%)

Close on Nov 18, 2026Market cap $460.59MP/E –Yield –

Crescent Biopharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Crescent Biopharma's revenue for the twelve months ending Dec 31, 2022 was $75.00K, down 93.5% year over year. For fiscal 2025 it was $10.84M, up 108340.0% from the year before. The highest annual figure on record is $20.07M in fiscal 2015.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.84M+108340.0%
FY2023Dec 31, 2023$10.00K-86.7%
FY2022Dec 31, 2022$75.00K-93.5%
FY2021Dec 31, 2021$1.16M-88.6%
FY2020Dec 31, 2020$10.16M+54834.8%
FY2016Dec 31, 2016$18.50K-99.9%
FY2015Dec 31, 2015$20.07M+33.6%
FY2014Dec 31, 2014$15.03M+276.4%
FY2013Dec 31, 2013$3.99M-73.8%
FY2012Dec 31, 2012$15.26M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0–
Q1 FY2026Mar 31, 2026$1.04M–
Q2 FY2025Jun 30, 2025$0-100.0%
Q1 FY2025Mar 31, 2025$0-100.0%
Q4 FY2022Dec 31, 2022$0-100.0%
Q3 FY2022Sep 30, 2022$0-100.0%
Q2 FY2022Jun 30, 2022$75.00K-92.9%
Q4 FY2021Dec 31, 2021$17.63K-89.2%
Q3 FY2021Sep 30, 2021$86.56K-91.3%
Q2 FY2021Jun 30, 2021$142–
Q1 FY2021Mar 31, 2021$1.06M-88.3%
Q4 FY2020Dec 31, 2020$162.94K–
Q3 FY2020Sep 30, 2020$1.00M+5305.4%
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$9.00M–
Q4 FY2016Dec 31, 2016$0–
Q3 FY2016Sep 30, 2016$18.50K–

More Crescent Biopharma figures

See a number that looks wrong?